Home Ingredients Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)
Stress & AnxietySleep HealthCognitive

Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)

Withania somnifera
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

Zenroot® is OmniActive's root-only ashwagandha (Withania somnifera) extract — standardized to 1.5% withanolides using USP methodology, with enhanced bioavailability enabling efficacy at an unusually low 125 mg/day dose. Root-only positioning matters: regulatory pressure on ashwagandha in Europe has focused on the leaf/aerial parts (higher withaferin A content), making root-only extracts the preferred form for long-term safety. Two 2025 peer-reviewed trials in Advances in Therapy support the 125 mg dose: (1) Bioavailability crossover (n=20) showing Zenroot 125 mg produced 2.1× higher absorption than a 600 mg 5%-withanolide reference and 1.3× higher than a 500 mg 10% reference; (2) 12-week RCT (n=90 adults with mild-to-moderate stress) showing significant decreases in Perceived Stress Scale in less than 30 days, improvements in sleep quality by day 28, and gains in mood and occasional anxiety symptoms vs placebo. Honest framing: low-dose efficacy backed by recent solid trials; the ashwagandha category has substantial class evidence and Zenroot offers a competitive bioavailability-enhanced low-dose option suitable for gummies and functional beverages.

Studied Dose 125 mg/day Zenroot (used in both 2025 published trials). The bioavailability advantage means this dose achieves equivalent or superior systemic withanolide exposure vs 500-600 mg of competing 5-10% withanolide extracts. Effects on Perceived Stress Scale measurable in under 30 days; sleep quality improvements by day 28; full mood and anxiety profile changes over 12 weeks. Take with food.
Active Compound Withania somnifera root-only extract, standardized to 1.5% total withanolides via USP method, with individual withanolide quantification (withanoside IV, withanolide A, 12-deoxywithastramonolide, withaferin A) per FDA guidance. Root-only positioning minimizes withaferin A content vs whole-plant or leaf-containing extracts.

Benefits

Stress reduction in under 30 days (Bengaluru 2025)

12-week randomized double-blind placebo-controlled trial in 90 adults aged 18-55 with mild-to-moderate stress. 125 mg/day Zenroot produced significant decrease in Perceived Stress Scale scores in less than 30 days vs placebo. Effect was supported by objective Mindfield eSense Skin Response measurement alongside the subjective scale. Published in Advances in Therapy 2025.

Supported by Trial 2

Sleep quality improvement (12-week trial)

Same 90-adult trial documented statistically significant improvements in sleep quality by day 28 vs both baseline and placebo. Effect sustained through the 12-week protocol. Sleep mechanism consistent with ashwagandha's broader adaptogenic profile — reducing nighttime cortisol and supporting calmer sleep onset.

Supported by Trial 2

2.1× higher bioavailability vs 600 mg 5% reference

Randomized double-blind single-dose crossover bioavailability study (n=20 healthy adults under fasting). 125 mg Zenroot achieved 2.1× higher total withanolide plasma absorption vs a 600 mg ashwagandha 5%-withanolide reference product, and 1.3× higher vs a 500 mg 10% reference. Established the low-dose efficacy rationale measurably.

Supported by Trial 1

Mood and occasional anxiety improvements

12-week trial outcomes included statistically significant improvements in mood state and severity of occasional anxiety symptoms vs placebo. Consistent with ashwagandha's traditional Ayurvedic use as a calming adaptogen. Mechanism likely involves HPA axis modulation and GABAergic activity.

Supported by Trial 2

Root-only sourcing for regulatory safety

European regulators have flagged concerns about ashwagandha aerial parts (leaves), which have higher withaferin A content potentially associated with rare hepatic adverse events. Root-only sourcing (the traditional Ayurvedic preparation) reduces this regulatory and safety concern, making Zenroot more suitable for European markets and long-term use.

Supported by Trial 1

Low-dose convenience for novel formats

The 125 mg low-dose advantage enables formulation in gummies, functional shots, ready-to-drink beverages, and other formats where higher mg doses wouldn't fit. Competing ashwagandha extracts at 500-600 mg are challenging for these formats. Excellent organoleptic profile (bland taste, dissolution) supports beverage applications.

Supported by Trial 1

Mechanism of action

1

HPA axis modulation

Ashwagandha withanolides modulate the hypothalamic-pituitary-adrenal axis, reducing baseline cortisol and dampening cortisol response to stressors. Multiple ashwagandha trials show 15-30% reductions in serum cortisol after 8-12 weeks. The HPA modulation underlies both stress and sleep benefits.

2

GABAergic activity

Withanolides bind to GABA-A receptors with modulatory effects similar in kind (but milder) to benzodiazepines. This GABAergic activity contributes to the calming nootropic profile — anxiolytic effects without sedation at typical clinical doses.

3

Enhanced bioavailability (Zenroot-specific)

OmniActive's proprietary extraction and standardization process delivers withanolides in a form with improved absorption — documented as 2.1× higher plasma withanolide exposure vs 600 mg 5%-withanolide reference. The mechanism appears to involve the natural withanolide profile and matrix rather than added bioavailability enhancers.

4

Antioxidant and anti-inflammatory effects

Withanolides have direct antioxidant activity and modulate inflammatory pathways (NF-κB, NLRP3 inflammasome). Chronic stress drives oxidative stress and inflammation; ashwagandha's antioxidant/anti-inflammatory effects complement its HPA axis modulation for broader stress resilience support.

Clinical trials

1
Zenroot Bioavailability Study — Advances in Therapy 2025

Randomized double-blind single-dose crossover comparative oral bioavailability study in 20 healthy adults under fasting conditions. Three arms: Zenroot 125 mg (1.5% withanolides), reference 600 mg (5% withanolides), reference 500 mg (10% withanolides). Plasma withanolide measurements at multiple time points over 24 hours. Outcome: Zenroot 125 mg achieved 2.1× higher absorption than the 600 mg 5% reference and 1.3× higher than the 500 mg 10% reference.

2
Zenroot for Stress, Sleep, Mood, Anxiety — Advances in Therapy 2025

12-week randomized double-blind placebo-controlled trial in 90 adults aged 18-55 with mild-to-moderate stress. Intervention: 125 mg/day Zenroot or placebo. Outcomes: significant decrease in Perceived Stress Scale and Mindfield eSense Skin Response in under 30 days; sleep quality improvement by day 28 vs baseline and placebo; improvements in mood state and severity of occasional anxiety symptoms over 12 weeks. Conducted at Bengaluru Neuro Center, Santosh Hospital.

Side effects and drug interactions

Common Potential side effects

Excellent tolerability profile in both 2025 trials.
Mild GI side effects rare.
Root-only sourcing minimizes withaferin A content and theoretical hepatic concerns associated with whole-plant or leaf-containing ashwagandha extracts (very rare reports of ashwagandha-associated hepatitis).
Mild sedation in some users — consistent with the calming adaptogenic profile.
Possible mild thyroid hormone elevation (ashwagandha may modestly increase T3/T4) — relevant for hyperthyroid patients to monitor.

Important Drug interactions

Sedatives and anxiolytics (benzodiazepines, barbiturates, z-drugs) — additive sedation; use caution.
Thyroid medications — ashwagandha may increase T3/T4; monitor and adjust thyroid medication dose if needed.
Immunosuppressants — ashwagandha may stimulate immune function; theoretical interaction with immunosuppressive therapy; consult prescriber.
Antidiabetic medications — mild hypoglycemic effects possible; monitor blood glucose.
Antihypertensives — mild additive BP-lowering possible.
Pregnancy and lactation — AVOID. Ashwagandha is traditionally contraindicated in pregnancy due to possible abortifacient effects in animal studies.

More Stress & Anxiety Ingredients

Muscle & Recovery
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…
Cognitive
Ashwagandha
Ashwagandha is an adaptogenic herb that may reduce stress, enhance mood, and support overa…
Cognitive
KSM-66®
KSM-66 Ashwagandha, a standardized root extract, promotes stress relief and cognitive clar…
Cognitive
Phosphatidylserine
Phosphatidylserine (PS) is a phospholipid concentrated in neuronal cell membranes (10-20%…

Explore Other Ingredients

Sleep Health
Valerian Root
Valerian root is one of the most widely used herbal sleep aids in Western medicine, with a…
Immune Support
Vitamin C
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin commonly used in supple…
Cognitive
Rhodiola Rosea
Rhodiola rosea is an adaptogenic herb from arctic and mountainous regions of Europe and As…

Frequently asked questions about Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)

What is Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)?

Zenroot® is OmniActive's root-only ashwagandha (Withania somnifera) extract — standardized to 1.

What does Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) do?

Ashwagandha withanolides modulate the hypothalamic-pituitary-adrenal axis, reducing baseline cortisol and dampening cortisol response to stressors. Multiple ashwagandha trials show 15-30% reductions in serum cortisol after 8-12 weeks. In clinical research, Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) has been studied for stress reduction in under 30 days (bengaluru 2025), sleep quality improvement (12-week trial), 2.1× higher bioavailability vs 600 mg 5% reference.

Who should take Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)?

Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) may be most relevant for people interested in stress & anxiety, sleep health, cognitive. It has been clinically studied for stress reduction in under 30 days (bengaluru 2025), sleep quality improvement (12-week trial), 2.1× higher bioavailability vs 600 mg 5% reference. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) take to work?

In clinical trials, effects have been measured at 30 days of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)?

For stress and mood goals, Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) can be taken in the morning, evening, or split through the day. Effects build gradually over weeks; daily consistency matters more than precise timing. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) worth taking?

Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive)?

The clinically studied dose for Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) is 125 mg/day Zenroot (used in both 2025 published trials). The bioavailability advantage means this dose achieves equivalent or superior systemic withanolide exposure vs 500-600 mg of competing 5-10% withanolide extracts. Effects on Perceived Stress Scale measurable in under 30 days; sleep quality improvements by day 28; full mood and anxiety profile changes over 12 weeks. Take with food.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) used for?

Zenroot® (Low-Dose Bioavailable Ashwagandha Root Extract — OmniActive) is studied for stress reduction in under 30 days (bengaluru 2025), sleep quality improvement (12-week trial), 2.1× higher bioavailability vs 600 mg 5% reference. 12-week randomized double-blind placebo-controlled trial in 90 adults aged 18-55 with mild-to-moderate stress. 125 mg/day Zenroot produced significant decrease in Perceived Stress Scale scores in less than 30 days vs placebo.